Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic Outcomes

BACKGROUND: Recombinant factor VIII Fc fusion protein (rFVIIIFc) is the first extended half-life (EHL) recombinant clotting factor with marketing authorization; it has been available in France since October 2016. However, data and literature about rFVIIIFc in clinical practice are scarce. OBJECTIVE:...

Descripción completa

Detalles Bibliográficos
Autores principales: Giraud, Romain, Delmotte, Nicolas, Gensollen, Sophie, Roche, Martine, Falaise, Céline, Chambost, Hervé, Roche, Manon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605945/
https://www.ncbi.nlm.nih.gov/pubmed/34170499
http://dx.doi.org/10.1007/s40801-021-00259-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605945/
https://www.ncbi.nlm.nih.gov/pubmed/34170499
http://dx.doi.org/10.1007/s40801-021-00259-2

Ejemplares similares